A dual-enzyme-like nanozyme adjuvant alleviates tumor hypoxia to enhance photothermally ferroptosis-immune synergistic tumor therapy.

ABSTRACT: Immune adjuvants play a critical role in cancer vaccines and emerging therapies. However, conventional adjuvants may fail to effectively stimulate cytotoxic T lymphocyte (CTL)-mediated immune responses. Nanozyme-based adjuvants, particularly manganese-based nanozymes, demonstrate significant potential by integrating enzymatic activity with immune modulation. Herein, we developed a dual-enzyme-like nanozyme adjuvant (Mn₃O₄&MLT@PDA-AS1411, MMPA) through the integration of Mn₃O₄ nanozyme and melatonin (MLT) using polydopamine, which alleviates tumor hypoxia to enhance photothermally augmented ferroptosis-immune synergistic therapy. The ferroptosis is cooperatively enhanced by Mn₃O₄ nanozyme-mediated reactive oxygen species gene

SUBMITTER: Chang P 

PROVIDER: S-EPMC12637074 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature